Skip to main content

Research Repository

Advanced Search

Outputs (11)

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial (2020)
Journal Article
Heaney, L. G., Busby, J., Hanratty, C. E., Djukanovic, R., Woodcock, A., Walker, S. M., …Yang, F. (2021). Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine, 9(1), 57-68. https://doi.org/10.1016/s2213-2600%2820%2930397-0

Background
Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driv... Read More about Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.

Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial (2020)
Journal Article
Pavord, I. D., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., …Toelle, B. (2020). Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respiratory Medicine, 8(7), 671-680. https://doi.org/10.1016/s2213-2600%2820%2930053-9

Background
Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are associated with important outcomes in mild asthma is unclear. In this prespecified subgroup analysis of a previously published open-label clinical trial, we aimed to asse... Read More about Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma (2019)
Journal Article
Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., …Weatherall, M. (2019). Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. New England Journal of Medicine, 380(21), 1-11. https://doi.org/10.1056/nejmoa1901963

BACKGROUND
In double-blind, placebo-controlled trials, budesonide–formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of... Read More about Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial (2018)
Journal Article
Hanratty, C. E., Matthews, J. G., Arron, J. R., Choy, D. F., Pavord, I. D., Bradding, P., …Heaney, L. G. (2018). A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. Trials, 19, Article 5. https://doi.org/10.1186/s13063-017-2384-7

Background: Patients with difficult-to-control asthma consume 50–60% of healthcare costs attributed to asthma and cost approximately five-times more than patients with mild stable disease. Recent evidence demonstrates that not all patients with asthm... Read More about A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

MMP-1 activation contributes to airway smooth muscle growth and asthma severity (2016)
Journal Article
Naveed, S.-U.-N., Clements, D., Jackson, D. J., Philp, C., Billington, C. K., Soomro, I. N., Reynolds, C., Harrison, T. W., Johnston, S. L., Shaw, D. E., & Johnson, S. R. (2017). MMP-1 activation contributes to airway smooth muscle growth and asthma severity. American Journal of Respiratory and Critical Care Medicine, 195(8), 1000-1009. https://doi.org/10.1164/rccm.201604-0822OC

Introduction: Matrix metalloproteinase-1 and mast cells are present in the airways of people with asthma. We hypothesised that matrix metalloproteinase-1 could be activated by mast cells and increase asthma severity. Methods: Patients with stable ast... Read More about MMP-1 activation contributes to airway smooth muscle growth and asthma severity.

The differential effects of azithromycin on the airway epithelium in vitro and in vivo (2016)
Journal Article
Slater, M., Torr, E., Harrison, T. W., Forrester, D. L., Knox, A., Shaw, D. E., & Sayers, I. (2016). The differential effects of azithromycin on the airway epithelium in vitro and in vivo. Physiological Reports, 4(18), 1-15. https://doi.org/10.14814/phy2.12960

Macrolides including azithromycin (AZM) can improve clinical symptoms in asthma regardless of infection status. The mechanisms underlying these benefi- cial effects are yet to be elucidated. The aim of this study was to determine the effect of AZM on... Read More about The differential effects of azithromycin on the airway epithelium in vitro and in vivo.

Azithromycin for Acute Exacerbations of Asthma: the AZALEA randomized clinical trial (2016)
Journal Article
Johnson, S. L., Szigeti, M., Cross, M., Brightling, C., Chaudhuri, R., Harrison, T. W., …Chauhan, A. (2016). Azithromycin for Acute Exacerbations of Asthma: the AZALEA randomized clinical trial. JAMA Internal Medicine, 176(11), https://doi.org/10.1001/jamainternmed.2016.5664

IMPORTANCE Guidelines recommend against antibiotic use to treat asthma attacks. A study with telithromycin reported benefit, but adverse reactions limit its use.
OBJECTIVE To determine whether azithromycin added to standard care for asthma attacks i... Read More about Azithromycin for Acute Exacerbations of Asthma: the AZALEA randomized clinical trial.

Untargeted metabolic profiling of saliva by liquid chromatography-mass spectrometry for the identification of potential diagnostic biomarkers of asthma (2016)
Journal Article
Malkar, A., Wilson, E., Harrison, T., Shaw, D. E., & Creaser, C. (in press). Untargeted metabolic profiling of saliva by liquid chromatography-mass spectrometry for the identification of potential diagnostic biomarkers of asthma. Analytical Methods, 8(27), 5407-5413. https://doi.org/10.1039/C6AY00938G

Current clinical tests employed to diagnose asthma are inaccurate and limited by their invasive nature. New metabolite profiling technologies offer an opportunity to improve asthma diagnosis using non-invasive sampling. A rapid analytical method for... Read More about Untargeted metabolic profiling of saliva by liquid chromatography-mass spectrometry for the identification of potential diagnostic biomarkers of asthma.

Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study (2015)
Journal Article
McKeever, T. M., Hearson, G., Housley, G., Reynolds, C., Kinnear, W., Harrison, T. W., Kelly, A.-M., & Shaw, D. E. (2016). Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study. Thorax, 71(3), 210-215. https://doi.org/10.1136/thoraxjnl-2015-207573

Introduction: Identifying acute hypercapnic respiratory failure is crucial in the initial management of acute exacerbations of COPD. Guidelines recommend obtaining arterial blood samples but these are more difficult to obtain than venous. We assessed... Read More about Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study.